Most drug stocks have been out of favor in 2023.
Pfizer was down 43.4% as of the market close Monday, while
Johnson & Johnson is down 16.4%. Despite Eli Lilly’s monster 66.8% gain on the year, amid investor frenzy over its
weight-loss drugs, the S&P 500 Pharmaceuticals index is down 2.3%.